Heron Therapeutics, Inc.
HRTX
$1.10
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.72% | -4.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.72% | -4.38% | |||
| Cost of Revenue | 20.27% | 19.14% | |||
| Gross Profit | -6.47% | -13.34% | |||
| SG&A Expenses | 3.36% | 4.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.93% | 8.64% | |||
| Operating Income | -150.03% | -151.90% | |||
| Income Before Tax | -634.78% | -190.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -634.78% | -190.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -634.78% | -190.36% | |||
| EBIT | -150.03% | -151.90% | |||
| EBITDA | -238.99% | -127.69% | |||
| EPS Basic | -562.58% | -190.12% | |||
| Normalized Basic EPS | -132.99% | -190.65% | |||
| EPS Diluted | -413.50% | -300.00% | |||
| Normalized Diluted EPS | -132.99% | -215.48% | |||
| Average Basic Shares Outstanding | 10.60% | 0.35% | |||
| Average Diluted Shares Outstanding | 10.60% | -21.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||